학술논문
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Document Type
Article
Author
Facon, Thierry ; Kumar, Shaji K; Plesner, Torben; Orlowski, Robert Z; Moreau, Philippe; Bahlis, Nizar; Basu, Supratik; Nahi, Hareth; Hulin, Cyrille; Quach, Hang; Goldschmidt, Hartmut; O'Dwyer, Michael; Perrot, Aurore; Venner, Christopher P; Weisel, Katja; Mace, Joseph R; Raje, Noopur; Tiab, Mourad; Macro, Margaret; Frenzel, Laurent; Leleu, Xavier; Ahmadi, Tahamtan; Wang, Jianping; Van Rampelbergh, Rian; Uhlar, Clarissa M; Tromp, Brenda; Delioukina, Maria; Vermeulen, Jessica; Usmani, Saad Z
Source
In The Lancet Oncology November 2021 22(11):1582-1596
Subject
Language
ISSN
1470-2045